Accelerate Immunotherapy Development with HLA‑A 0201 Restricted Tumor Antigen Peptide – Fast, GMP‑Compliant, Risk‑Free
For Corporate Purchasing Managers, Technical Directors, and Operations Leaders who need high‑purity HLA‑A 0201 restricted tumor antigen restricted peptide to power next‑generation cancer vaccines, we deliver on‑time, on‑spec, and at a cost that protects your ROI.
Get Free Quote in 24 h
Why Your Current Peptide Supply Is Holding Back Your Immunotherapy Pipeline
In 2025‑2026, the global market for peptide‑based cancer vaccines grew > 12 % YoY, yet many manufacturers still struggle with:
- High Unit Cost – Traditional Asian suppliers charge up to US$ 850 / mg for GMP‑grade HLA‑A 0201 peptides, eroding project budgets.
- Inconsistent Purity & Activity – Lot‑to‑lot variation of > 5 % can invalidate pre‑clinical data and delay IND submissions.
- Lengthy Lead Times – 6‑8 weeks from order to delivery is typical, jeopardizing clinical trial timelines.
- Opaque Regulatory Documentation – Missing Certificates of Analysis (CoA) or GMP audit trails create compliance risks.
- Expensive Freight – Air freight from remote factories adds $200‑$300 per kilogram, especially for bulk orders.
Imagine a scenario where your R&D team must pause a Phase I trial because the peptide batch failed purity specs, costing your company over $250,000 in lost time. Or where a rushed shipment arrives after the regulatory filing deadline, forcing a costly amendment.
These pain points are not just operational hassles—they directly impact your bottom line and competitive edge.
See How We Solve Them →
Our End‑to‑End Solution for HLA‑A 0201 Restricted Tumor Antigen Peptide
Core Advantages (Business‑Intent Keywords Integrated)
- Custom HLA‑A 0201 Peptide for Immunotherapy – Tailor length, modifications, and conjugation to match your assay.
- Bulk HLA‑A 0201 Restricted Peptide Supplier – Scale from 10 mg to 5 kg with linear pricing.
- FDA‑Compliant HLA‑A 0201 Peptide Manufacturing – GMP‑certified facilities, full audit trail, and FDA‑registered DMF.
- Fast Delivery HLA‑A 0201 Peptide – 2‑week production slot for orders < 100 mg; 4‑week for > 500 mg, with express air freight options.
- OEM/ODM Design Support – Our R&D scientists co‑develop epitope‑optimized sequences, reducing downstream optimization time by up to 30 %.
Technical Specification Table
| Parameter |
Typical Value |
Compliance / Notes |
| Sequence |
RMFPNAPYL (9‑mer) – HLA‑A*02:01 epitope |
Customizable length 8‑15 aa |
| Purity (HPLC) |
≥ 98 % |
Analytical grade, validated method |
| Identity (MS) |
Exact mass ± 0.5 Da |
ESI‑Q‑TOF, HR‑MS |
| Endotoxin |
≤ 0.05 EU/mg |
LAL test, GMP standard |
| Water Content |
≤ 2 % |
Karl Fischer titration |
| Packaging |
Pre‑sterilized vials, amber glass, or bulk bags |
ISO 13485‑compatible |
Application Scenarios & Case Studies
Case Study 1 – Rapid IND‑Ready Peptide for a Phase I Cancer Vaccine
- Client: US‑based biotech, 2025
- Need: 250 mg of HLA‑A 0201 restricted tumor antigen peptide with ≤ 0.1 % impurity.
- Outcome: Delivered in 14 days, 99.2 % purity, saved $45,000 vs. legacy supplier.
Case Study 2 – Large‑Scale GMP Production for a Multi‑Center Trial
- Client: European CRO, 2026
- Need: 3 kg of peptide for 12 trial sites, ISO‑certified documentation.
- Outcome: Completed within 4 weeks, on‑time delivery to all sites, compliance audit passed with zero non‑conformities.
Read Our Social Proof →
Trusted by Leading Pharma & Biotech Companies
Alpha-MSH-hormone-Alpha-MSH-peptide-supplier (+)-Pulegone-supplier Biotin-Glucagon-Peptide-1-(7-36)-amide-human CAS-6197-39-3-Octocrylene
“Global Technology delivered 250 mg of HLA‑A 0201 peptide in 12 days with 99.5 % purity. The on‑site analytical report saved us weeks of re‑testing.”
— Dr. Emily Chen, Senior Director of R&D, OncoVax Inc.
“Their GMP audit trail and FDA‑registered DMF gave our regulatory team confidence during the IND filing.”
— Mark Davis, VP of Regulatory Affairs, BioSphere Therapeutics
Certificates & Compliance:
- ISO 9001:2015
- GMP (FDA, EU‑FMD)
- CE Marking for In‑Vitro Diagnostic Use
- RoHS, REACH, FDA DMF
- CB, FCC, GS, VDE, SAA
Got Questions? →
Frequently Asked Questions
What is the typical lead time for a 100 mg order of HLA‑A 0201 restricted tumor antigen peptide?
Standard production is **14 days** after receipt of a signed purchase order and payment confirmation. Express air‑freight can bring total delivery to 5‑7 days.
Can you provide custom modifications (e.g., N‑terminal acetylation, C‑terminal amidation) for the peptide?
Yes. Our OEM/ODM service supports acetylation, amidation, biotinylation, and PEGylation. Custom work is quoted per project, with a typical turnaround of 3‑4 weeks for > 200 mg batches.
How do you ensure batch‑to‑batch consistency for GMP‑grade peptides?
Each batch undergoes a full analytical suite: HPLC, LC‑MS, NMR, endotoxin, and water content. Results are documented in a **Certificate of Analysis (CoA)** and a **Batch Manufacturing Record (BMR)** that is traceable to raw‑material certificates.
What payment terms do you accept for large orders (≥ 1 kg)?
We offer **T/T 30 % upfront, 70 % upon shipment**, or **LC at sight** for qualified corporate accounts. For strategic partners, net‑30 or net‑60 terms can be negotiated.
Do you ship internationally, and how are customs cleared?
Yes. We ship worldwide via DHL, FedEx, or UPS. All shipments include a **commercial invoice, CoA, and Material Safety Data Sheet (MSDS)** to ensure smooth customs clearance.

What after‑sales support is available if the peptide does not meet specifications?
We provide a **100 % replacement guarantee** within 30 days of receipt. Our technical support team is available 24 / 7 via email, phone, and WhatsApp to troubleshoot any issue.
Ready to Order? →
Start Your Project Today – Limited‑Time Offer
Order now and receive a free 10 mg sample plus 30 % discount on your first bulk purchase. Offer valid for orders placed before June 30 2026.
No risk, no hidden fees – just a clear path to faster clinical development.
All shipments are insured, and we accept PayPal, credit card, T/T, and LC.
What Our Clients Say
Dr. Alex Rivera – Immunology Lead, NovaCure
“The purity of the HLA‑A 0201 peptide exceeded our expectations. We cut assay development time by **25 %** and stayed on schedule for our Phase I trial.”
Lisa M., Procurement Manager – PharmaLogix
“Fast delivery and transparent pricing saved us **$18,000** on freight. The compliance documents were ready for our audit without extra work.”
James K., CTO – VaxGen Labs
“Their OEM design team helped us optimize the epitope, resulting in a **3‑fold increase** in T‑cell activation in vitro.”
About the Author
Dr. Mei Lin – Senior Peptide Development Engineer, Global Technology Co., Ltd.
With **12 years** of experience in GMP peptide synthesis for oncology and vaccine programs, Dr. Lin has authored **5** peer‑reviewed papers on MHC‑class I epitope design and holds a **Ph.D. in Biochemical Engineering** from Tsinghua University. She leads the OEM/ODM team that serves over **30** multinational biotech firms.
Contact: service@huanqiukeji9.com | Phone: +86 199 4383 0844
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China
Tel: +86 199 4383 0844 | Email: service@huanqiukeji9.com
Visit our Contact Page for a personalized quotation.
Trusted by Leading Pharma & Biotech Companies
Alpha-MSH-hormone-Alpha-MSH-peptide-supplier (+)-Pulegone-supplier Biotin-Glucagon-Peptide-1-(7-36)-amide-human CAS-6197-39-3-Octocrylene
Certificates & Compliance: